The Food and Drug Administration (FDA) has proposed that the labels on all antidepressant medications be updated to include warnings about the increased risk of suicidal thinking and behavior in teenagers and young adults during the first two months of treatment.
Makers of antidepressant medications now have 30 days to submit their revised product labeling and revised Medication Guides to FDA for review.
Below is a list of antidepressant medications that are affected by the new suicidal tendencies (suicidal thinking and behavior, known as suicidality) verbiage proposed by the FDA:
Celexa (citalopram hydrobromide)
Desyrel (trazodone HCl)
Effexor (venlafaxine HCl)
Lexapro (escitalopram hydrobromide)
Nardil (phenelzine sulfate)
Norpramin (desipramine HCl) Pamelor (nortriptyline)
Parnate (tranylcypromine sulfate)
Paxil (paroxetine HCl)
Pexeva (paroxetine mesylate)
Prozac (fluoxetine HCl)
Sarafem (fluoxetine HCl)
Tofranil-PM (imipramine pamoate)
Wellbutrin (bupropion HCl)
Zoloft (sertraline HCl)
Zyban (bupropion HCl)
If you or someone you know is taking anti-depressants and has had thoughts of suicide, consult with your doctor immediately!